|
1
|
Hortobagyi GN, de la Garza SJ, Pritchard
K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M,
Namer M, et al: The global breast cancer burden: Variations in
epidemiology and survival. Clin Breast Cancer. 6:391–401. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kohler BA, Sherman RL, Howlader N, Jemal
A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, et
al: Annual report to the nation on the status of cancer, 1975–2011,
featuring incidence of breast cancer subtypes by race/ethnicity,
poverty and state. J Natl Cancer Inst. 107:djv0482015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delmonico L, Moreira Ados S, Franco MF,
Esteves EB, Scherrer L, Gallo CV, do Nascimento CM, Ornellas MH, de
Azevedo CM and Alves G: CDKN2A (p14(ARF)/p16(INK4a)) and ATM
promoter methylation in patients with impalpable breast lesions.
Hum Pathol. 46:1540–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delmonico L, Costa MASM, Fournier MV,
Romano SO, Nascimento CMD, Barbosa AS, Moreira ADS, Scherrer LR,
Ornellas MHF and Alves G: Mutation profiling in the PIK3CA, TP53,
and CDKN2A genes in circulating free DNA and impalpable breast
lesions. Ann Diagn Pathol. 39:30–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cady B, Stone MD, Schuler JG, Thakur R,
Wanner MA and Lavin PT: The new era in breast cancer: Invasion,
size, and nodal involvement dramatically decreasing as a result of
mammographic screening. Arch Surg. 131:301–308. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peters NH, Borel Rinkes IH, Mali WP, van
den Bosch MA, Storm RK, Plaisier PW, de Boer E, van Overbeeke AJ
and Peeters PH: Breast MRI in nonpalpable breast lesions: A
randomized trial with diagnostic and therapeutic
outcome-MONET-study. Trials. 8:402007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ribelles N, Perez-Villa L, Jerez JM,
Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E,
Marquez A, et al: Pattern of recurrence of early breast cancer is
different according to intrinsic subtype and proliferative index.
Breast Cancer Res. 15:R982013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clarke M, Collins R, Darby S, Davies C,
Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al:
Effects of radiotherapy and of differences in the extent of surgery
for early breast cancer on local recurrence and 15 year survival:
An overview of the randomised trials. Lancet. 366:2087–2106. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gomis RR and Gawrzak S: Tumor cell
dormancy. Mol Oncol. 11:62–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naume B, Borgen E, Beiske K, Herstad TK,
Ravnås G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S and
Kvalheim G: Immunomagnetic techniques for the enrichment and
detection of isolated breast carcinoma cells in bone marrow and
peripheral blood. J Hematother. 6:103–114. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krishnamurthy S, Cristofanilli M, Singh B,
Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A,
Jackson S and Lucci A: Detection of minimal residual disease in
blood and bone marrow in early stage breast cancer. Cancer.
116:3330–3337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bidard FC, Mathiot C, Delaloge S, Brain E,
Giachetti S, de Cremoux P, Marty M and Pierga JY: Single
circulating tumor cell detection and overall survival in
nonmetastatic breast cancer. Ann Oncol. 21:729–733. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hall CS, Karhade MG, Bowman Bauldry JB,
Valad LM, Kuerer HM, DeSnyder SM and Lucci A: Prognostic value of
circulating tumor cells identified before surgical resection in
nonmetastatic breast cancer patients. J Am Coll Surg. 223:20–29.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parashar S, Cheishvili D, Mahmood N,
Arakelian A, Tanvir I, Khan HA, Kremer R, Mihalcioiu C, Szyf M and
Rabbani SA: DNA methylation signatures of breast cancer in
peripheral T-cells. BMC Cancer. 18:5742018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan Z, Yu H, Cuk K, Zhang Y and Brenner
H: Whole-Blood DNA methylation markers in early detection of breast
cancer: A systematic literature review. Cancer Epidemiol Biomarkers
Prev. 28:496–505. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang Q, Cheng J, Cao X, Surowy H and
Burwinkel B: Blood-based DNA methylation as biomarker for breast
cancer: A systematic review. Clin Epigenetics. 8:1152016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sturgeon SR, Pilsner JR, Arcaro KF, Ikuma
K, Wu H, Kim SM, Chopra-Tandon N, Karpf AR, Ziegler RG, Schairer C,
et al: White blood cell DNA methylation and risk of breast cancer
in the prostate, lung, colorectal, and ovarian cancer screening
(PLCO). Breast Cancer Res. 19:942017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao X, Tang Q, Holland-Letz T, Gündert M,
Cuk K, Schott S, Heil J, Golatta M, Sohn C, Schneeweiss A and
Burwinkel B: Evaluation of promoter methylation of RASSF1A and ATM
in peripheral blood of breast cancer patients and healthy control
individuals. Int J Mol Sci. 19:E9002018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brennan K, Garcia-Closas M, Orr N,
Fletcher O, Jones M, Ashworth A, Swerdlow A and Thorne H; KConFab
Investigators, : Intragenic ATM methylation in peripheral blood DNA
as a biomarker of breast cancer risk. Cancer Res. 72:2304–2313.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Z, Bolick SC, DeRoo LA, Weinberg CR,
Sandler DP and Taylor JA: Epigenome-wide association study of
breast cancer using prospectively collected sister study samples. J
Natl Cancer Inst. 105:694–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Askari M, Sobti RC, Nikbakht M and Sharma
SC: Promoter hypermethylation of tumor suppressor genes (p14/ARF
and p16/INK4a): Case control study in north Indian population. Mol
Biol Rep. 40:4921–4928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shan M, Yin H, Li J, Li X, Wang D, Su Y,
Niu M, Zhong Z, Wang J, Zhang X, et al: Detection of aberrant
methylation of a six-gene panel in serum DNA for diagnosis of
breast cancer. Oncotarget. 7:18485–18494. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmed M and Rahman N: ATM and breast
cancer susceptibility. Oncogene. 25:5906–5911. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flanagan JM, Munoz-Alegre M, Henderson S,
Tang T, Sun P, Johnson N, Fletcher O, Dos Santos Silva I, Peto J,
Boshoff C, et al: Gene-Body hypermethylation ATM in peripheral
blood DNA of bilateral breast cancer patients. Hum Mol Genet.
18:1332–1342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Begam N, Jamil K and Raju SG: Promoter
hypermethylation of the ATM gene as a novel biomarker for breast
cancer. Asian Pac J Cancer Prev. 18:3003–3009. 2017.PubMed/NCBI
|
|
27
|
Majchrzak-Celinska A, Paluszczak J,
Szalata M, Barciszewska AM, Nowak S, Kleszcz R, Sherba A and
Baer-Dubowska W: The methylation of a panel of genes differentiates
low-grade from high-grade gliomas. Tumour Biol. 36:3831–3841. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Q, Su X, Ai L, Li M, Fan CY and
Weiss LM: Promoter hypermethylation of multiple genes in gastric
lymphoma. Leuk Lymphoma. 48:1988–1996. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai AH, Tong JH, To KF, Chan MW, Man EP,
Lo KW, Lee JF, Sung JJ and Leung WK: Promoter hypermethylation of
tumor-related genes in the progression of colorectal neoplasia. Int
J Cancer. 112:846–853. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spitzwieser M, Entfellner E, Werner B,
Pulverer W, Pfeiler G, Hacker S and Cichna-Markl M:
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and
tumor-distant tissues from breast cancer patients. BMC Cancer.
17:2602017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wijetunga NA, Belbin TJ, Burk RD, Whitney
K, Abadi M, Greally JM, Einstein MH and Schlecht NF: Novel
epigenetic changes in CDKN2A are associated with progression of
cervical intraepithelial neoplasia. Gynecol Oncol. 142:566–573.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alhejaily A, Day AG, Feilotter HE, Baetz T
and Lebrun DP: Inactivation of the CDKN2 tumor-suppressor gene by
deletion or methylation is common at diagnosis in follicular
lymphoma and associated with poor clinical outcome. Clin Cancer
Res. 20:1676–1686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang BH, Li YY, Han JZ, Zhou LY, Lv YQ,
Zhang HL and Zhao L: Gene methylation as a powerful biomarker for
detection and screening of non-small cell lung cancer in blood.
Oncotarget. 8:31692–31704. 2017.PubMed/NCBI
|
|
35
|
Ding K, Chen X, Wang Y, Liu H, Song W, Li
L, Wang G, Song J, Shao Z and Fu R: Plasma DNA methylation of p16
and shp1 in patients with B cell non-Hodgkin lymphoma. Int J Clin
Oncol. 22:585–592. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Delmonico L, Areias VR, Pinto RC, Matos
Cda S, Rosa MF, De Azevedo CM and Alves G: Protein identification
from dried nipple aspirate fluid on guthrie cards using mass
spectrometry. Mol Med Rep. 12:159–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of Tumours of the Breast.
4th. IARC Press; Lyon: pp. p2402012
|
|
38
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Esteller M, Tortola S, Toyota M, Capella
G, Peinado MA, Baylin SB and Herman JG: Hypermethylation-associated
inactivation of p14(ARF) is independent of p16(INK4a) methylation
and p53 mutational status. Cancer Res. 60:129–133. 2000.PubMed/NCBI
|
|
41
|
Vo QN, Kim WJ, Cvitanovic L, Boudreau DA,
Ginzinger DG and Brown KD: The ATM gene is a target for epigenetic
silencing in locally advanced breast cancer. Oncogene.
23:9432–9437. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heitzer E, Haque IS, Roberts CES and
Speicher MR: Current and future perspectives of liquid biopsies in
genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Herceg Z, Ghantous A, Wild CP, Sklias A,
Casati L, Duthie SJ, Fry R, Issa JP, Kellermayer R, Koturbash I, et
al: Roadmap for investigating epigenome deregulation and
environmental of cancer. Int J Cancer. 142:874–882. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ambatipudi S, Cuenin C, Hernandez-Vargas
H, Ghantous A, Le Calvez-Kelm F, Kaaks R, Barrdahl M, Boeing H,
Aleksandrova K, Trichopoulou A, et al: Tobacco smoking-associated
genome-wide DNA methylation changes in the EPIC study. Epigenomics.
8:599–618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Weihrauch-Blüher S, Richter M and Staege
MS: Body weight regulation, socioeconomic status and epigenetic
alterations. Metabolism. 85:109–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
